Edoxaban did not differ from dalteparin for treatment of cancer-associated venous thromboembolism


In patients with cancer who have acute symptomatic or asymptomatic (incidental) venous thromboembolism (VTE), is treatment with edoxaban similar to low-molecular-weight heparin for recurrent VTE and major bleeding?

The study

Who? The study included 1046 patients who had cancer that was active or had been diagnosed within the previous 2 years. Patients were included if they had lower limb deep vein thrombosis (DVT) or pulmonary embolism (PE) in segmental or proximal pulmonary arteries and required anticoagulation for at least 6 months.

What? The study compared edoxaban after 5 days of therapeutic low-molecular-weight heparin (LMWH) with dalteparin.




Any therapeutic dose LMWH for 5 days followed by edoxaban (Lixiana or Savaysa), 60 mg, for 6-12 months.

Edoxaban, 30 mg, was used for patients who had reduced renal function, low body weight, or were taking medications that interfere with drug clearance (e.g., P-glycoprotein inhibitors).

Dalteparin, 200 IU/kg, for 30 days followed by 150 IU/kg for 6-12 months.

What the researchers found

Patients in the edoxaban and dalteparin groups did not differ for the combined outcome of recurrent VTE or major bleeding.

3 more patients out of 100 taking edoxaban had major bleeding compared with dalteparin.

The bottom line

In patients with cancer-associated VTE, edoxaban was similar to dalteparin for combined major bleeding or recurrent VTE. There was a trend toward less recurrent VTE in the edoxaban group, but this group also experienced more major bleeds.

Summary of findings

Edoxaban vs dalteparin in patients who have cancer-associated VTE


Rate of events

with edoxaban

Rate of events

with dalteparin

Absolute effect of edoxaban

at 1 year

Recurrent VTE or major bleeding



No effect*

Recurrent VTE



No effect*
Recurrent DVT3.6%6.7%No effect*
Recurrent PE5.2%5.3%No effect*
Major bleeding6.9%4.0%

About 3 more patients out of 100

had major bleeding

Clinically relevant non-major bleeding14.6%11.1%No effect*
Death from any cause39.5%36.6%No effect*

*Although the rates for the 2 groups look different, the differences were not statistically significant—this means that the difference could simply be due to chance rather than due to the different treatments.

This Evidence Summary is based on the following article:

Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378(7):615-24.  PubMed

Why was this study so important?

Largely due to the results of the CLOT trial,1 the use of LMWH has been the standard of care for treating cancer-associated thrombosis for several years. However, not surprisingly, patients do not like having to inject themselves daily or twice daily for 6 months or longer. When newer direct oral anticoagulants came on the market, there was great interest in finding out if they were as good as LMWH at protecting patients from VTE while avoiding the need for injections.

The multinational Hokusai VTE Cancer trial described above enrolled patients with various types of cancer to compare edoxaban (a new direct oral anticoagulant) and dalteparin (LMWH) for recurrent VTE and bleeding . Edoxaban had slightly lower rates of recurrent thrombosis but at the price of slightly more bleeding events. Bleeding occurred more frequently in patients with gastrointestinal cancers, which suggests that patients with these types of malignancies may not be ideal candidates for direct oral anticoagulants.  

It is important to note that LMWH dose was capped at 18,000 units (even when the weight-based dose for the patient should have been higher), and there was a protocolized decrease in dose with platelets less than 100 x 109/L (not typical for clinical practice but consistent with the CLOT trial protocol1). Also, we do not know if the results with edoxaban can be extapolated to the other direct oral anticoagulants that are currently available. However, the Hokusai Trial does show that at least some cancer patients may be able to take a pill instead of a needle.

Doctor, I have cancer. Can I take a pill instead of a needle to treat my DVT or PE?

According to the Hokusai trial, taking a new pill (edoxaban) after 5 days of needles is as safe as using injections (dalteparin) on a daily basis for treating DVT or PE due to cancer. While this is good news, pills may not be the best choice for all patients. For example, if you vomit frequently, pills may not absorb properly, which could put you at risk for forming new blood clots. Also, some drugs, including some chemotherapy drugs, interact with the new pill, which means it would be safer to use the needles because they do not interact with other drugs. Lastly, the pills may not be covered by all insurance plans. Your individual case will need to be carefully reviewed before changing your anticoagulant treatment.

1Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53.

Published: Friday, May 11, 2018

This Evidence Summary is also available in other formats:

Read the Patient Summary